CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
|
|
- Chrystal Oliver
- 5 years ago
- Views:
Transcription
1 CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd FA, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Antonia SJ
2 Rationale for Combined Immune Checkpoint Blockade With Nivolumab and Ipilimumab in Non-Small Cell Lung Cancer Nivolumab and ipilimumab enhance T-cell antitumor activity through distinct and complementary mechanisms 1 The combination of nivolumab and ipilimumab is approved in the US and EU for metastatic melanoma and has demonstrated encouraging clinical benefit across a number of tumor types 2- PFS With Nivo or Nivo + Ipi vs Ipi Alone in Previously Untreated Advanced Melanoma Proportion Alive and Progression-Free Nivo + Ipi Nivo Ipi Months Nivolumab monotherapy is approved in the US and EU for adults with locally advanced/metastatic NSCLC with progression either during or after platinum-doublet chemotherapy 1. Callahan MK, et al. Front Oncol. 21;4: Wolchok JD, et al. N Engl J Med. 213;369(2): Hammers HJ, et al. J Clin Oncol. 21;33(suppl): Larkin J, et al. N Engl J Med. 21;373(1): Rizvi NA, et al. Presented at: The 16 th World Conference on Lung Cancer, September 6-9, 21; Denver, CO, United States: ORAL2.. Ipi, ipilimumab; Nivo, nivolumab; NSCLC, non-small cell lung cancer; PFS, progression-free survival
3 Phase I CheckMate 12 Study Design: Nivolumab Plus Ipilimumab in First-Line NSCLC Stage IIIB/IV NSCLC (any histology), no prior chemotherapy for advanced disease, ECOG PS or 1 Previous cohorts: Nivo 1 + Ipi 3 q 3 w x 4 Nivo 3 + Ipi 1 q 3 w x 4 Nivo 1 + Ipi 1 q 3 w x 4 Nivo 1 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w + Ipi 1 q 12 w Nivo 3 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w until disease progression a or unacceptable toxicity Until disease progression a or unacceptable toxicity Primary endpoint: safety and tolerability Secondary endpoints: ORR (RECIST v1.1) and PFS rate at 24 weeks Exploratory endpoints: OS, efficacy by PD-L1 expression The safety and tolerability of the nivo ipi combination was improved with less frequent ipilimumab dosing Schedules with nivolumab 3 mg/kg also showed increased clinical efficacy in a previous analysis Here, we report longer follow-up on nivolumab 3 mg/kg plus ipilimumab schedules b ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate; OS, overall survival, PD-L1, programmed cell-death ligand 1; RECIST, response evaluation criteria in solid tumors. Rizvi NA, et al. Presented at: The 16 th World Conference on Lung Cancer, September 6-9, 21; Denver, CO, United States: ORAL2.. a Patients tolerating study treatment permitted to continue treatment beyond RECIST v1.1-defined progression if considered to be deriving clinical benefit; b February 216 database lock; Ipilimumab and nivolumab dosing are shown in mg/kg IV (eg, nivo 1 = nivolumab 1 mg/kg IV)
4 Phase I CheckMate 12 Study Design: Nivolumab Plus Ipilimumab in First-Line NSCLC Stage IIIB/IV NSCLC (any histology), no prior chemotherapy for advanced disease, ECOG PS or 1 Previous cohorts: Nivo 1 + Ipi 3 q 3 w x 4 Nivo 3 + Ipi 1 q 3 w x 4 Nivo 1 + Ipi 1 q 3 w x 4 Nivo 1 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w + Ipi 1 q 12 w Nivo 3 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w until disease progression a or unacceptable toxicity Until disease progression a or unacceptable toxicity Primary endpoint: safety and tolerability Secondary endpoints: ORR (RECIST v1.1) and PFS rate at 24 weeks Exploratory endpoints: OS, efficacy by PD-L1 expression The safety and tolerability of the nivolumab ipilimumab combination was improved with less frequent ipilimumab dosing Schedules with nivolumab 3 mg/kg also showed increased clinical efficacy in a previous analysis Here, we report longer follow-up on nivolumab 3 mg/kg plus ipilimumab schedules b. Rizvi NA, et al. Presented at: The 16 th World Conference on Lung Cancer, September 6-9, 21; Denver, CO, United States: ORAL2.. a Patients tolerating study treatment permitted to continue treatment beyond RECIST v1.1-defined progression if considered to be deriving clinical benefit; b February 216 database lock; Ipilimumab and nivolumab dosing are shown in mg/kg IV (eg, nivo 1 = nivolumab 1 mg/kg IV)
5 Phase I CheckMate 12 Study Design: Nivolumab Plus Ipilimumab in First-Line NSCLC Stage IIIB/IV NSCLC (any histology), no prior chemotherapy for advanced disease, ECOG PS or 1 Previous cohorts: Nivo 1 + Ipi 3 q 3 w x 4 Nivo 3 + Ipi 1 q 3 w x 4 Nivo 1 + Ipi 1 q 3 w x 4 Nivo 1 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w + Ipi 1 q 12 w Nivo 3 q 2 w + Ipi 1 q 6 w Nivo 3 q 2 w until disease progression a or unacceptable toxicity Until disease progression a or unacceptable toxicity Primary endpoint: safety and tolerability Secondary endpoints: ORR (RECIST v1.1) and PFS rate at 24 weeks Exploratory endpoints: OS, efficacy by PD-L1 expression The safety and tolerability of the nivolumab ipilimumab combination was improved with less frequent ipilimumab dosing Schedules with nivolumab 3 mg/kg also showed increased clinical efficacy in a previous analysis Here, we report longer follow-up on nivolumab 3 mg/kg plus ipilimumab schedules b. Rizvi NA, et al. Presented at: The 16 th World Conference on Lung Cancer, September 6-9, 21; Denver, CO, United States: ORAL2.. a Patients tolerating study treatment permitted to continue treatment beyond RECIST v1.1-defined progression if considered to be deriving clinical benefit; b February 216 database lock; Ipilimumab and nivolumab dosing are shown in mg/kg IV (eg, nivo 1 = nivolumab 1 mg/kg IV)
6 Baseline Patient Characteristics Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Median age, years (range) 68 (-91) 62 (47-87) Male, % 4 62 Nonsquamous histology, % 82 8 Disease stage, % Stage IIIB Stage IV ECOG PS, % 1 Smoking status, % Never Former/current EGFR mutation status, % Mutant Wildtype Unknown PD-L1 quantifiable, N (%) 1%, n/n (%) %, n/n (%) 1%, n/n (%) 2%, n/n (%) %, n/n (%) (82) 21/31 (68) 16/31 (2) 13/31 (42) 1/31 (32) 6/31 (19) (77) 23/3 (77) 19/3 (63) 1/3 () 8/3 (27) 7/3 (23)
7 Baseline Patient Characteristics Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Median age, years (range) 68 (-91) 62 (47-87) Male, % 4 62 Nonsquamous histology, % 82 8 Disease stage, % Stage IIIB Stage IV ECOG PS, % 1 Smoking status, % Never Former/current EGFR mutation status, % Mutant Wildtype Unknown PD-L1 quantifiable, N (%) 1%, n/n (%) %, n/n (%) 1%, n/n (%) 2%, n/n (%) %, n/n (%) (82) 21/31 (68) 16/31 (2) 13/31 (42) 1/31 (32) 6/31 (19) (77) 23/3 (77) 19/3 (63) 1/3 () 8/3 (27) 7/3 (23)
8 Baseline Patient Characteristics Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Median age, years (range) 68 (-91) 62 (47-87) Male, % 4 62 Nonsquamous histology, % 82 8 Disease stage, % Stage IIIB Stage IV ECOG PS, % 1 Smoking status, % Never Former/current EGFR mutation status, % Mutant Wildtype Unknown PD-L1 quantifiable, N (%) 1%, n/n (%) %, n/n (%) 1%, n/n (%) 2%, n/n (%) %, n/n (%) (82) 21/31 (68) 16/31 (2) 13/31 (42) 1/31 (32) 6/31 (19) (77) 23/3 (77) 19/3 (63) 1/3 () 8/3 (27) 7/3 (23)
9 Safety Summary Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Any Grade Grade 3-4 Any Grade Grade 3-4 Treatment-related AEs, % Treatment-related AEs leading to discontinuation, % There were no treatment-related deaths Treatment-related grade 3-4 AEs led to discontinuation at a third of the rate seen with older combination arms using higher or more frequent doses of ipilimumab 6 Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock AE, adverse event 6. Antonia SJ, et al. Presented at: The Chicago Multidisciplinary Symposium in Thoracic Oncology 214 Annual Meeting; October 3-November 1, 214; Chicago, IL, United States: Poster 168.
10 Safety Summary Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Nivo 3 Q 2 W (n = 2) Any Grade Grade 3-4 Any Grade Grade 3-4 Any Grade Grade 3-4 Treatment-related AEs, % Treatment-related AEs leading to discontinuation, % There were no treatment-related deaths Treatment-related grade 3-4 AEs led to discontinuation at a third of the rate seen with older combination arms using higher or more frequent doses of ipilimumab 6 Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock 6. Antonia SJ, et al. Presented at: The Chicago Multidisciplinary Symposium in Thoracic Oncology 214 Annual Meeting; October 3-November 1, 214; Chicago, IL, United States: Poster 168.
11 Treatment-Related Select AEs Nivo 33 Q Q2W 2 W + Ipi 1 Q Q12W W Nivo 3 Q Q2W 2 W + Ipi 1 Q6WQ 6 W Nivo 3 Q Q2W2 W 6 (n = 38) (n = 39) (n = 2) Total Patients With an Event, % Grade 1 2 Grade 3 4 All treatment-related pulmonary events were pneumonitis Grade 1-2 hypersensitivity/infusion reaction occurred in % and 6% of patients in the nivo 3 q 2 w + ipi 1 q 12 w and monotherapy groups, respectively Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock; Select AEs are those with potential immunologic etiology that require frequent monitoring/intervention
12 Summary of Efficacy Nivo 3 Q 2 W + Ipi 1 Q 12 W (n = 38) Nivo 3 Q 2 W + Ipi 1 Q 6 W (n = 39) Nivo 3 Q 2 W (n = 2) Confirmed ORR, % (9% CI) 47 (31, 64) 39 (23, ) 23 (13, 37) Median duration of response, months (9% CI) NR (11.3, NR) NR (8.4, NR) NR (.7, NR) Median length of follow-up, months (range) 12.9 (.9-18.) 11.8 ( ) 14.3 (.2-3.1) Best overall response, % Complete response Partial response Stable disease Progressive disease Unable to determine Median PFS, months (9% CI) 8.1 (.6, 13.6) 3.9 (2.6, 13.2) 3.6 (2.3, 6.6) 1-year OS rate, % (9% CI) NC 69 (2, 81) 73 (9, 83) Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock except for OS data, which are based on an August 21 database lock NC, not calculated (when >2% of patients are censored); NR, not reached 8
13 Kinetics of Response Change in Target Lesion Size From Baseline, % Nivo 3 Q 2 W + Ipi 1 Q 6 W Time, Months 12/1 responders (8%) in the q 6 w arm and 14/18 responders (78%) in the q 12 w arm had a response by time of first scan (week 11) 12/1 responders (8%) in the q 6 w arm and 12/18 responders (67%) in the q 12 w arm had an ongoing response at time of database lock PD, progressive disease; SD, stable disease No response (PD + SD) Response First response Includes all patients with baseline target lesion and 1 post-baseline assessment of target lesion (n = 33)
14 Efficacy by Tumor PD-L1 Expression ORR, % (n/n) <1% PD-L1 1% PD-L1 % PD-L1 Median PFS (9% CI), months <1% PD-L1 1% PD-L1 % PD-L1 1-year OS rate (9% CI), % <1% PD-L1 1% PD-L1 % PD-L1 Nivo 3 Q 2 W + Ipi 1 Q 12 W 3 (3/1) 7 (12/21) 1 (6/6) 4.7 (.9, NR) 8.1 (.6, NR) 13.6 (6.4, NR) NC 9 (66, 97) NC Nivo 3 Q 2 W + Ipi 1 Q 6 W Nivo 3 Q 2 W (/7) 7 (13/23) 86 (6/7) 2.4 (1.7, 2.9) 1.6 (3.6, NR) NR (7.8, NR) NC 83 (6, 93) 1 (1, 1) 14 (2/14) 28 (9/32) (6/12) 6.6 (2., 11.2) 3. (2.2, 6.6) 8.4 (2.2, NR) 79 (47, 93) 69 (, 82) 83 (48, 96) Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock except for OS data, which are based on an August 21 database lock
15 Efficacy Across all Tumor PD-L1 Expression Levels 1 Nivo 3 Q 2 W + Ipi 1 Q 6 / 12 W (pooled) Nivo 3 Q 2 W ORR, % n = All <1% 1% % 1% 2% % Overall <1% 1% % 1% PD-L1 Expression 2% % Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock
16 Efficacy By Smoking and EGFR Mutation Status 1 Smoking Status 1 EGFR Mutation Status 8 Nivo 3 Q2W + Ipi 1 Q6/12W (pooled) a 8 Nivo 3 Q2W + Ipi 1 Q6/12W (pooled) ORR, % Nivo 3 Q2W ORR, % 6 4 c Nivo 3 Q2W b n Never smoked Current/former smoker n 8 Mutant 7 4 Wild-type 3 Never Smoker Current/Former Smoker EGFR Mutant EGFR Wild-Type Combination data based on a February 216 database lock; monotherapy data based on a March 21 database lock a Excludes 1 patient with unknown smoking status (nivo 3 q 2 w + ipi 1 q 6 w) b In patients with non-squamous histology only c Must be interpreted with caution: of these 4 responders, 1 did not have a classical exon 19 deletion or L88R EGFR activating mutations, 3 were former/current smokers, and 3 had high PD-L1 expression levels
17 Case of Pathological Complete Response in One Patient Treated With Nivo 3 Q 2 W + Ipi 1 Q 6 W 4-year-old male (former smoker, 2 packyear) with metastatic large-cell lung cancer (PD-L1 <1% a ) 3% total tumor size reduction by RECIST Radiographic residual lesions in the lung and mediastinal lymph nodes, without distant disease Change From Baseline, % Partial Response Treatment Initiated Treatment Discontinuation (due to rash and grade 2 pneumonitis) Date Resection Before Nivo + Ipi Therapy Following Nivo + Ipi Therapy No Viable Tumor in Resected Residual Lesion Right upper lobe wedge resection (nodule #1) Mar-216 a Patient was included as having partial response and PD-L1 expression unknown in analysis at time of database lock Courtesy of Dr. William Travis, MSKCC
18 Nivolumab Plus Ipilimumab in First-Line NSCLC: Conclusions Nivolumab 3 mg/kg q 2 w plus ipilimumab 1 mg/kg (q 6 w or q 12 w) is well tolerated Frequency of treatment-related AEs leading to discontinuation was similar to nivolumab monotherapy (11% 13%) There were no treatment-related deaths Nivolumab plus ipilimumab has promising efficacy 39% 47% ORR; median duration of response not reached Efficacy with nivolumab plus ipilimumab is enhanced with increasing PD-L1 expression 1% tumor PD-L1 expression: 7% ORR; 83% 9% 1-year OS rates % tumor PD-L1 expression: 92% (12/13) ORR Nivolumab 3 mg/kg q 2 w plus ipilimumab 1 mg/kg q 6 w schedule is being evaluated in further studies, including the phase 3 CheckMate 227 trial (NCT )
Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationPD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer
PD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer Rebecca S. Heist, MD, MPH Abstract The recent success of PD-1 and PD-L1 inhibitors in
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationImmunotherapy in Non-Small Cell Lung Cancer
Immunotherapy in Non-Small Cell Lung Cancer Renato G. Martins Stephen H. Petersdorf Endowed Chair in Cancer Care Associate Medical Director, Solid Tumor Adult Oncology, Seattle Cancer Care Alliance Professor,
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationCheckpoint inhibitors in the first-line treatment of non-small cell lung cancer
380 Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer L. Decoster, MD 1, K. Vekens, MD 2, S. Mignon, MD 1, D. Schallier, MD, PhD 1, J. De Grève, MD, PhD 1 SUMMARY Antibodies
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationLead team presentation:
Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationInmunoterapia en cáncer de pulmón. Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro
Inmunoterapia en cáncer de pulmón Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Current Therapeutic Landscape for NSCLC Current treatment strategies in NSCLC Various
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationIMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationHarnessing the immune system to combat cancer. Gary Middleton, University of Birmingham
Harnessing the immune system to combat cancer Gary Middleton, University of Birmingham Going nowhere fast Vansteenkiste J et al. Lancet Oncol. 2016 Apr 27. pii: S1470-2045(16)00099-1. Immune checkpoints
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More information